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• Participants with reduced adiponectin levels are more likely to develop endometrial cancer 21 
regardless of their BMI status, history of hypertension or diabetes. 22 
• When considering participants with high BMI or a history of diabetes, increased leptin 23 
levels confer a greater risk of endometrial cancer 24 
• Larger studies are required to establish the role of TNF-α and IL-6 in the development of 25 
endometrial cancer 26 





To investigate the association between circulating levels of adipocytokines (adiponectin, leptin, 30 
tumour necrosis factor alpha (TNFα), interleukin 6 (IL-6)) and growth factors (insulin-like 31 
growth factor I (IGF-I) and II (IGF-II)), and the risk of endometrial cancer. 32 
Methods 33 
Cochrane, CINAHL, Embase, Medline and Web of Science were searched for English-34 
language manuscripts published between January 2000 and August 2018 using the following 35 
string of words: cancer and endometrial and (obesity or BMI) and (adiponectin or TNF* or 36 
IGF-I or IGF-II or IL-6 or leptin). 37 
Results 38 
Twenty articles were included in this meta-analysis, which corresponded to 18 studies involving 39 
2921 endometrial carcinoma cases and 5302 controls. Fourteen articles reported circulating 40 
levels for adiponectin, seven for leptin, three for TNFα, three for IL-6 and one for IGF- I. No 41 
article reported values for IGF- II. 42 
Patients with circulating adiponectin levels in the highest tertile had decreased endometrial 43 
cancer risk compared to women with levels in the lowest tertile, (summary of odds ratio (SOR) 44 
0.51, 95% CI: 0.38-0.69, p<0.00001). Women with circulating leptin concentrations in the 45 
highest tertile had increased endometrial cancer risk compared to women with concentrations 46 
in the lowest tertile (SOR 2.19, 95% CI: 1.45-3.30, p=0.0002). There was no difference in 47 
cancer risk between participants with the highest TNFα and IL-6 levels compared to the lowest 48 





Endometrial cancer risk is inversely affected by adiponectin and leptin levels. There appears to 52 
be no relationship between TNF-α and IL- 6 and the overall risk of endometrial cancer.  53 
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1. Background 54 
The exact biological mechanism underlying the development of endometrial cancer is still 55 
poorly understood. In the UK, endometrial cancer is the 4th most common female cancer; 56 
approximately 9000 women were diagnosed with endometrial cancer in 2015 [1]. Worldwide, 57 
320 000 new cases of endometrial cancer were diagnosed in 2012 [2]. 58 
Obesity is a well-recognised risk factor for endometrial cancer; however, the relationship 59 
between obesity and endometrial cancer is complex and likely to involve multiple biological 60 
pathways. Sex steroid and insulin pathways, chronic inflammation and alterations in circulating 61 
levels of adipokines have all been suggested as potential mechanisms affecting endometrial 62 
cancer risk [3-5]. Whilst elevated levels of endogenous oestrogens cannot justify alone the 63 
correlation between obesity and endometrial cancer, experimental studies have shown that 64 
adipokines, associated with hyperinsulinemia and insulin resistance, and inflammatory 65 
cytokines, associated to increased adiposity, may be also involved in the development of 66 
endometrial cancer [6].  67 
Adiponectin, leptin, tumour necrosis factor alpha (TNFα), interleukin 6 (IL-6), insulin-like 68 
growth factor I and II (IGF-I and IGF-II), collectively termed adipocytokines, are hormones 69 
and cytokines secreted from adipocytes, and potentially key circulating molecules associated to 70 
endometrial cancer risk [7, 8].  71 
Adiponectin, the most abundant circulating adipocytokines, plays an important role in 72 
regulating insulin and glucose metabolism, by promoting insulin secretion from pancreatic β 73 
cells and facilitating insulin up-take in the liver [9-12]. Moreover, adiponectin has anti 74 
proliferative properties and, by activating AMP activated protein kinase (AMPK), inhibits cell 75 
growth, angiogenesis and promotes apoptosis in malignant cells [13]. Because of its properties 76 
and the fact that adiponectin is decreased in obesity, insulin resistance and type 2 diabetes, all 77 
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independent risk’s factors for endometrial cancer, circulating adiponectin levels may be an 78 
important factor in endometrial cancer.  79 
Leptin affects the activity of several cell types and its main function involves regulating energy 80 
intake and expenditure [14]. It has a role in glucose metabolism, as well as in the immune 81 
system. Leptin is also secreted by cancer cells and its levels have been reported to be increased 82 
in endometrial cancer and hyperplasia compared to controls with normal endometrium [15]. 83 
TNFα and IL-6 are pro-inflammatory cytokines released by macrophages within adipose tissue 84 
and have been implicated in tumourigenesis. TNFα promotes cellular proliferation and prevents 85 
apoptosis by activating NFκB, [16], whereas IL-6 initiates tumour development and progression 86 
through several pathways [17]. Both cytokines have been reported to be increased in 87 
endometrial cancer and their pro-inflammatory actions play a role in cancer growth and 88 
metastasis by inducing reactive oxygen species and subsequent DNA damage and DNA repair 89 
inhibition [18]. IL-6 was found to be overexpressed in the stroma of endometrial cancer cells 90 
and TNFα was associated with poor survival [19, 20]. However, other studies have not reported 91 
such an increase and found no difference in the expression of IL-6 in endometrial cancer and at 92 
the various clinical stages [21].  93 
IGF-I and IGF-II are growth factors involved in growth and development [22]. They are 94 
expressed in the normal development of the endometrium and also stimulated by oestrogen in 95 
the uterus [23]. Epidemiological, clinical and experimental data have identified IGF-I and II as 96 
important players in endometrial cancers. IGFs are thought to play a role in the initiation of 97 
endometrial cancer due to oestrogen increasing the synthesis and expression of IGF-I which 98 
stimulates cell proliferation thereby initiating endometrial cancer [24]; whereas IGF-II 99 
expression was increased in advanced endometrial cancer compared to early stage endometrial 100 
cancer [25]. Relative few studies have assessed the correlations between endometrial cancer 101 
risk and circulating levels of IGF axis components: however a large degree of variability 102 
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between studies and results was reported probably reflecting the complexity of this hormonal 103 
system and the involvement of additional (hormonal or other) factors that can either positively 104 
or negatively impinge upon IGF axis components.  105 
Although evidences from in vitro and ex-vivo studies for a causal role of adipocytokines in 106 
endometrial cancer are available, results from epidemiological studies are inconsistent. A 107 
number of meta-analyses [26-28] have previously summarised epidemiological studies 108 
investigating the relationship between circulating adiponectin and leptin concentrations and 109 
endometrial cancer risk, however, to date, no meta-analysis has been performed to assess the 110 
relationship between circulating levels of the pro-inflammatory cytokines, TNFα and IL-6, or 111 
growth factors, IGF-I and IGF-II, and the risk of endometrial cancer. This study further clarifies 112 
the association between circulating levels of leptin and adiponectin, and endometrial cancer, 113 
and aimed to systematically assess the relationship between cytokines (IL-6 and TNFα) and 114 
growth factors (IGF-I and IGF-II) levels with endometrial cancer risk via a meta-analysis of 115 
observational studies. 116 
 117 
2. Methods 118 
2.1. Literature search 119 
Meta-analysis was performed and reported by adopting the Meta-analyses of Observational 120 
Studies in Epidemiology (MOOSE) guidelines [29]. English-language manuscripts published 121 
between January 2000 and August 2018 were searched from the databases: Cochrane, 122 
CINAHL, Embase, Medline and Web of Science. The following string of words was used for 123 
searches in all databases – cancer and endometrial and (obesity or BMI) and (adiponectin or 124 
TNF* or IGF-I or IGF-II or IL-6 or leptin). 125 
 126 
2.2. Selection of studies and exclusion criteria 127 
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Published studies were included if they met the following criteria: the study i) used an 128 
epidemiologic study design (e.g. case–control, case-cohort, nested case-control and cohort 129 
study); ii) provided information on circulating adiponectin, leptin, TNFα, IL-6, IGF-I, IGF-II 130 
concentrations as exposure of interest; iii) reported endometrial cancer as the outcome of 131 
interest; and iv) reported usable risk estimates (e.g. odds ratio, risk ratio or relative risk with 132 
95% confidence intervals between circulating adipocytokines levels and endometrial cancer 133 
risk). In addition, if more than one study was conducted in the same population, the most recent 134 
report or the report with the most applicable estimates was selected for analysis.  135 
Published studies were excluded by the following exclusion criteria: i) non epidemiological 136 
studies, reviews without original data, ecological studies, editorials and case reports; ii) the 137 
study reported the risk estimates that could not be summarized (i.e. reported the risk estimates 138 
without 95% CIs); and iii) the study reported exclusively on endometrial cancer mortality. All 139 
study selection and exclusion procedures were carried out by two independent investigators 140 
(PEE and GB). If there was discordance, a third independent reviewer, GAB would make the 141 
final decision. 142 
 143 
2.3. Data Extraction 144 
The following key data were extracted from each included study: first author’s name, 145 
publication year, study country, study design, number, ages and BMI of cases/controls, assay 146 
methods, risk estimates, and matched or adjusted factors including age, body mass index (BMI), 147 
menopausal status, whether they have had diabetes mellitus (DM) or hypertension, hormone 148 
replacement therapy (HRT) usage, parity or whether they smoked. 149 
 150 
2.4. Statistical analysis 151 
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Review Manager software, Version 5.3, was used to perform the meta-analysis: inverse 152 
variance, odds ratio and random effect were chosen as statistical method, effect measure and 153 
analysis model, respectively. The risk estimates were analysed as an estimation of odds ratio 154 
(OR) or relative risk (RR) for simplicity. People with the levels of exposure in the top tertile 155 
were compared with those in the bottom tertile. If the highest tertile (T3) and the lowest tertile 156 
(T1) were not available from the individual studies [30-37], a scaling method similar to Danesh 157 
et al. [38] and used by Gong et al. [26] was applied: a scaling factor of 2.18 divided by 2.54 158 
times the log OR for comparison of the top and bottom quartiles, or a scaling factor of 2.18 159 
times the log OR for 1 standard deviation difference in the baseline levels of adiponectin or 160 
leptin. In addition, some of the studies [6, 39] used the highest category of adiponectin rather 161 
than the lower category as comparison: an effective count method described by Hamling and 162 
colleagues [40], was therefore used to transform the comparison to the lowest tertile (T1). To 163 
assess the relationship between circulating adipocytokines and the risk of endometrial cancer, 164 
the summary of odds ratio (SOR) with 95% CI was estimated. This was performed using a 165 
random effect model of analysis. Chi-Squared test was used to assess the variation across the 166 
studies, which was included in the forest plots. Heterogeneity across the studies was analysed 167 
using the I2 statistics [41] and results were defined as heterogenous for an I2 > 50%. All 168 
statistical tests were two-sided. p < 0.05 were considered to be statistically significant. 169 
Sensitivity analysis was performed to assess the influence of individual studies on the pooled 170 
OR and 95% CI by excluding each study in turn. 171 
Heterogeneity of the study results were explored by using stratified analyses and subgroup 172 
analyses. These analyses included design of the study, fasting status for the collection of the 173 
blood samples and the type of assay method used. Subgroup analyses to identify potential 174 
confounders included BMI, hypertension, diabetes and menopausal status. A variable was 175 
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considered confounding if they were found to be significantly associated with endometrial 176 
cancer p <0.05 on the univariate analysis.  177 
 178 
3. Results 179 
3.1. Search Results and publication characteristics 180 
The database searches identified 473 publications. A total of 427 studies were excluded on title 181 
and abstract review as they did not meet the inclusion criteria as shown in Figure 1. The 182 
remaining 46 studies were reviewed for further details and full text retrieved. Twenty-six 183 
studies were excluded for not containing OR values, risk ratio or relative risk with 95% CI. 184 
Therefore, a total of 20 articles were included in this meta-analysis, which corresponded to 18 185 
studies involving 2921 endometrial carcinoma cases and 5302 controls. Fourteen articles 186 
reported circulating levels for adiponectin [6, 8, 31, 36, 37, 39, 42-49], 7 for leptin [8, 30, 36, 187 
43, 44, 47, 48] 3 for TNFα [34, 35, 50], 3 for IL-6 [33, 35, 50] and 1 for IGF-I [51]. No article 188 
reported values for IGF-II. The characteristics of these studies, all published between 2002 and 189 
2015, are presented in Table 1.  190 
 191 
3.2. Adiponectin and its relationship to endometrial cancer risk 192 
In this current meta-analysis, fourteen studies evaluated adiponectin and its relationship to 193 
endometrial cancer [6, 8, 31, 36, 37, 39, 42-49]. Two thousand and twenty-four endometrial 194 
cancer cases and 3,593 controls were assessed in 9 retrospective studies (8 case control studies 195 
[6, 31, 36, 37, 42-45] and 1 cross sectional-controlled study [39]) and 5 prospective studies 196 
(nested case control studies) [8, 46-49] (Table 1). Combined data showed a significant 197 
difference between the risks of developing endometrial cancer in women with the highest 198 
adiponectin levels compared to the lowest levels. Women with adiponectin concentrations in 199 
the highest tertile had a reduced risk (~0.5 times) of endometrial cancer compared to women 200 
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with adiponectin concentration levels in the lowest tertile (SOR 0.51, 95% CI: 0.38-0.69 201 
p<0.00001). There was significant heterogeneity, I2=77% p<0.00001 (Figure 2). 202 
Sensitivity analysis was performed to determine whether any particular study had a greater 203 
degree of influence between the association of adiponectin’s levels and the risk of endometrial 204 
cancer. Omitting each study one at a time and analysing the SOR of the rest of the studies, the 205 
SOR ranged from 0.48 (95% CI: 0.35-0.66, I2=79%, p<0.00001) when omitting Soliman et al., 206 
(2011) [46] study to 0.58 (95% CI: 0.45-0.75, I2=67% p=0.0002) when omitting Soliman et al., 207 
(2006) [6]. No single study had a larger influence over the other studies when assessing the 208 
association between adiponectin and endometrial cancer risk.  209 
Stratifying by study design revealed a SOR of 0.64 (95% CI: 0.41-0.99, p=0.05) for prospective 210 
studies [8, 46-49] and a SOR of 0.45 (95% CI: 0.29-0.68, p=0.0001) for the retrospective studies 211 
(Table 2) [6, 31, 36, 37, 39, 42-45]. The heterogeneity was lower for the prospective studies 212 
(56%, p=0.06) compared to the retrospective studies (83%, p<0.00001). There were variations 213 
in the type of blood samples used as well as the method used to measure the concentration of 214 
adiponectin. Eight studies [8, 31, 36, 37, 39, 43, 44, 47] used fasting samples to measure 215 
adiponectin and in the other six [6, 42, 45, 46, 48, 49], it was not clear whether the blood 216 
samples were fasted or postprandial. The point estimate for studies using fasting samples was 217 
0.51 (95% CI: 0.34-0.76, p=0.0009) and for the non-fasting studies, it was 0.51 (95% CI: 0.32-218 
0.81, p=0.004). Eleven studies used an ELISA to measure adiponectin concentrations [6, 8, 36, 219 
37, 39, 42, 43, 44, 46, 47, 49] and 3 studies used RIA/IMRA [31, 45, 48]. The point estimate 220 
of SOR in the studies using the ELISA method was similar to the studies using RIA/IMRA 221 
(SOR 0.53 vs 0.45). Within prospective studies, there was no significant heterogeneity (I2=56% 222 
p=0.06), whereas there was within retrospective studies (I2=83% p<0.00001). Within studies 223 
using fasting or non-fasting blood samples, there was significant heterogeneity (p=0.04 and 224 
p<0.00001, respectively). The studies using ELISA demonstrated statistically significant 225 
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heterogeneity (79% p<0.00001) whereas the one using RIA/IMRA did not (p=0.45). However 226 
there was no evidence of significant heterogeneity between subgroups detected by meta-227 
regression analyses (Table 2). 228 
Raised BMI, hypertension, diabetes and menopause are all risk factors for endometrial cancer. 229 
Sub-analyses were performed to assess for potential confounding factors. When considering 230 
BMI [6, 8, 31, 37, 39, 42-46, 49], the association between adiponectin levels and endometrial 231 
cancer risk is maintained (SOR 0.46, 95% CI: 0.31-0.69, p=0.0002, I2=81%, p<0.00001). When 232 
considering hypertension [6, 36, 37, 42, 44, 47], diabetes [6, 37, 42, 44, 46-48], or menopause 233 
status [8, 31, 36, 37, 39, 42, 44, 47, 48], a statistically significant association with endometrial 234 
cancers was maintained in the groups with hypertension (SOR 0.57, 95% CI: 0.36-0.91, p=0.02, 235 
I2=81% p<0.0001), diabetes (SOR 0.6, 95% CI: 0.38-0.94, p=0.03, I2=79% p<0.001) and post 236 
menopause (SOR 0.56, 95% CI: 0.40-0.80, p=0.001, I2=70% p=0.0007). This association was 237 
not lost in those without these conditions (Table 2).  238 
 239 
3.3. Leptin and its relationship to endometrial cancer risk 240 
A total of seven studies [8, 30, 36, 43, 44, 47, 48]; four retrospective [30, 36, 43, 44] and three 241 
prospective [8, 47, 48], assessed the association between circulating leptin concentrations and 242 
the risk of endometrial cancer. Three studies were nested case controls [8, 47, 48], and four 243 
were case control studies [30, 36, 43, 44]. One thousand, one hundred and ninety-nine 244 
endometrial cancers cases and 2076 control participants were assessed in the seven studies. The 245 
forest plot of the combined data (Figure 3) demonstrated a summary of OR of 2.19 (95% CI: 246 
1.45-3.30, p=0.0002). These results suggest a significant difference between the risk of 247 
developing endometrial cancer in individuals with the highest leptin levels versus the lowest 248 
levels. Women with leptin concentrations in the highest tertile had 2.19 times increased risk of 249 
13 
 
endometrial cancer compared to women with leptin concentrations in the lowest tertile. There 250 
was variation between the studies, with significant heterogeneity, I2 =64%, p=0.01.  251 
Sensitivity analysis was performed to determine whether any particular study had a greater 252 
degree of influence between the association of leptin and the risk of endometrial cancer. 253 
Omitting one study at a time and analysing the SOR of the rest of the studies, the SOR ranged 254 
from 1.99 (95% CI: 1.37-2.91 p=0.0003, I2=58%, p=0.03) when omitting Wu et al., (2014) [8] 255 
to 2.50 (95% CI: 1.84-3.40 p<0.00001, I2=13% p=0.330) when omitting Friedenreich et al., 256 
(2012) [36]. No single study had a larger influence over the other studies when assessing the 257 
association between leptin and endometrial cancer risk. 258 
When stratifying by study design (Table 2), the prospective studies [8, 47, 48] had a higher 259 
SOR of 3.32 (95% CI: 1.98-5.56 p<0.00001, I2=15%, p=0.31) compared to the retrospective 260 
studies’ SOR of 1.67 (95% CI: 1.09-2.57 p=0.02, I2=56%, p=0.08) [30, 36, 43, 44]. There were 261 
variations between the type of samples used and the measurement of leptin concentration; 6 262 
studies used fasting blood samples [8, 30, 36, 43, 44, 47] and 1 used a post prandial sample 263 
[48]. When comparing the type of samples, the point estimate of SOR for studies using non 264 
fasting blood samples was higher than the SOR for studies using fasting blood samples (2.77 265 
vs 2.10). The concentration of leptin was either measured using an ELISA [8, 36, 43, 47] or 266 
RIA [44, 48], in 4 and 2 studies, respectively. In a further study, leptin was measured using an 267 
IMRA [30]. The point estimate of SOR for studies using ELISA was 2.27 (95% CI: 1.16-4.42 268 
p=0.02, I2=75%, p=0.007) and for the studies using RIA/IMRA was 2.45 (95% CI: 1.67-3.59 269 
p<0.00001, I2=0%, p=0.45). Within prospective or retrospective studies there was no significant 270 
heterogeneity (I2=15% p=0.31, I2=56% p=0.08, respectively), however there was evidence of 271 
significant heterogeneity (p=0.04) between subgroups detected by meta-regression analyses 272 
(Table 2). Within studies using fasting blood samples [8, 30, 36, 43, 44, 47] and measuring 273 
leptin levels by ELISA [8, 36, 43, 47], there was significant heterogeneity (I2=65% p=0.01 and 274 
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I2=75% p=0.007, respectively), whereas the one using non-fasting blood samples and 275 
RIA/IMRA did not (n/a and p=0.45). There was no evidence of significant heterogeneity 276 
between the two subgroups detected by meta-regression analyses (Table 2). 277 
Both pre and post-menopausal women were included in these studies. Other factors that were 278 
matched/adjusted included BMI (n=4) [8, 30, 43, 44], hypertension (n=3) [36, 44, 47], a history 279 
of diabetes (n=3) [44, 47, 48] and post-menopausal status (n=5) [8, 30, 44, 47, 48]. When BMI 280 
is not considered [36, 47, 48], the overall association between leptin levels and the risk of 281 
developing endometrial cancer is reduced to borderline levels, p=0.05 (SOR 2.05, 95% CI 0.99-282 
4.25, I2=80% p=0.007). When considering patients with hypertension [36, 44, 47], the overall 283 
association between leptin levels and the risk of endometrial cancer is borderline (p=0.06, SOR 284 
1.99, 95% CI 0.98-4.04) whereas the overall association is increased when considering patients 285 
with diabetes [44, 47, 48], (p<0.00001, SOR 2.80, 95% CI 1.93-4.05). When post-menopausal 286 
status is not considered [36, 43], the overall association between leptin levels and the risk of 287 
developing endometrial cancer is lost, p=0.18 (SOR 1.49, 95% CI: 0.83-2.70). There was 288 
significant heterogeneity (I2=76%, p=0.02) in those studies that recorded hypertension 289 
compared to those studies that did not (I2=42%, p=0.16). For those studies that did not adjust 290 
for the presence of diabetes in its participants, the heterogeneity was higher (I2=68%, p=0.02) 291 
compared to those studies that consider diabetes as confounding factor (I2=0%, p=0.91). 292 
Similarly, for those studies that did not adjust for post-menopausal status, the heterogeneity was 293 
higher (I2=73%, p=0.05) compared to those studies that consider it as confounding factor 294 
(I2=16%, p=0.31). No evidence of significant heterogeneity between BMI, hypertension, 295 
diabetes and post-menopausal status subgroups was detected by meta-regression analyses 296 




3.4. TNFα, IL-6 and IGF-I and their relationship to endometrial cancer risk 299 
The paucity of studies analysing TNFα, IL-6 and IGF-I and their association with the risk of 300 
endometrial cancer is evident (Table 1) [33, 34, 35, 50, 51]. Two studies (one prospective [35] 301 
and one retrospective [50]) assessed both TNFα and IL-6 in a single cohort and a further 2 302 
studies (both prospective) assessed TNF-α [34] and IL-6 [33] only. There was only one study 303 
(prospective) investigating the role of IGF-I [51] and the risk of endometrial cancer. The total 304 
number of endometrial cancer and control cases for TNF-α was 940 and 1781 respectively, and 305 
for IL-6, it was 975 and 1837, respectively. The prospective study assessing IGF-I and its 306 
correlation with endometrial cancer risk had 166 cases and 315 controls.  307 
From the meta-analyses, there appeared to be no association between circulating levels of TNFα 308 
or IL-6 and overall risk of developing endometrial cancer (SOR=1.27, 95% CI: 0.88-1.83 309 
p=0.20, SOR=1.20, 95% CI: 0.89-1.63, p=0.23, respectively) (Figures 4 A and B). 310 
Heterogeneity was not present for either TNFα studies or IL-6 studies (I2=65% p=0.06 for 311 
TNFα, and I2= 42% p=0.18 for IL-6).  312 
Sensitivity analysis was performed to determine whether any single study had a greater degree 313 
of influence between the association of TNFα and the risk of endometrial cancer. When Wang 314 
et al., (2011) [35] was excluded, the SOR was 1.22 (95% CI: 0.77-1.93 p=0.39, I2 =78% 315 
p=0.030); excluding the study performed by Freidenreich et al., (2013) [50], the SOR was 1.58 316 
(95% CI: 1.13-2.22 p=0.007, I2=0%, p=0.92) and finally excluding the study performed by 317 
Dossus et al., (2011) [34], the SOR was 1.10 (95% CI: 0.77-1.56 p=0.59, I2 =36%, p=0.21). 318 
There are differences between the 3 studies which could explain the change in SOR; the Wang 319 
study [35] was a prospective study and the studies by Friedenreich et al., (2013) [50] and Dossus 320 
et al., (2011) [34] were retrospective and prospective studies, respectively. The participants in 321 
the Wang et al., (2011) [35] study were postmenopausal women who were not using any 322 
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hormone treatments. Both pre- and post–menopausal women were included in the other 2 323 
studies and some participants in these 2 studies were also noted to be using hormones. 324 
Sensitivity analysis was also performed to determine whether any single study had a greater 325 
degree of influence between the association of IL-6 and endometrial cancer risk. The SOR 326 
ranged from 1.06 (95% CI: 0.76-1.49 p=0.72, I2=18%, p=0.27), when omitting the Dossus et 327 
al, (2010) [33] to a SOR of 1.29 (95% CI: 0.97-1.70 p=0.08, I2=37% p=0.21, when excluding 328 
the Wang et al., (2011) [35] study. Excluding the Friedenreich et al., (2013) [50] study, the 329 
SOR was 1.15 (95% CI: 0.56-2.34 p=0.71, I2= 66%, p=0.09). 330 
Only one prospective study [51] investigated the association of pre-diagnostic blood 331 
concentrations of IGF-I and other factors associated to hyperinsulinemia with endometrial 332 
cancer risk. While increased circulating C-peptide levels were associated with increased 333 
endometrial cancer risk, the risk was unrelated to IGF-I levels (OR 0.90, 95% CI 0.44-1.82, p 334 
=0.54) when case-control pairs were matched for study cohort, age at recruitment into the study, 335 
menopausal status, and adjusted for BMI and HRT use.  336 
 337 
4. Discussion 338 
Inflammation, an important factor in the development and progression of cancer, has been 339 
implicated in the link between obesity and cancer [52, 53]. Adiponectin, leptin, TNF-α, IL-6 340 
and IGF-I are biological factors that are involved in different stages of the inflammatory 341 
pathway. To the best of our knowledge, this study is the most updated meta-analysis examining 342 
the relationship between circulating levels of adiponectin and leptin, and endometrial cancer; 343 
and the first one to assess the association between TNFα, IL-6, IGF-I and IGF-II and 344 
endometrial cancer risk. Our findings indicated that decreased circulating levels of adiponectin 345 
and increased levels of leptin are associated with increased endometrial cancer risk, whereas no 346 
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difference in cancer risk were observed between participants with the highest TNFα and IL-6 347 
levels. 348 
The paucity of studies reported in the literature investigating the link between the 349 
adipocytokines and endometrial cancer is evident; between 2000 and 2018, only 20 publications 350 
were found in the literature that met the inclusion criteria set. Undertaking a systematic review 351 
and meta-analysis increased population size enhancing the accuracy and precision of the 352 
findings from the various studies and allowing a greater understanding of the association 353 
between adipocytokines and endometrial cancer risk. Our analyses concurred with other 354 
reported studies [43, 48] on the association between adiponectin and leptin concentration levels 355 
and endometrial cancer risk: increased adiponectin serum levels and decreased leptin levels are 356 
associated with an overall decreased risk of endometrial cancer. It was found that women with 357 
higher levels of adiponectin had the risk of developing endometrial cancer decreased by half 358 
compared to those women with lower levels of adiponectin. Women with high levels of leptin 359 
had a two-fold increased risk of developing endometrial cancer compared to women with low 360 
levels of leptin. Similarly to the findings in this meta-analysis, low serum adiponectin levels 361 
and high serum leptin levels have been associated to increased risk of other types of cancer (e.g. 362 
colon and breast cancer) [54, 55]. In colorectal cancer patients, the association between TNFα, 363 
adiponectin and leptin has also been assessed concluding that leptin levels correlated with TNFα 364 
levels and that TNFα levels were an independent predictor of increased leptin levels [54]. Such 365 
association may be present in endometrial cancer, and leptin and TNFα may act synergistically 366 
to promote the development of endometrial cancer due to evidence that leptin promotes low 367 
grade inflammation by elevating levels of TNFα [56].  368 
The studies reported by Dallal et al., (2013) [47] and Soliman et al., (2011) [46] did not find an 369 
association between adiponectin serum levels and endometrial cancer risk, possibly due to the 370 
limited numbers of cases and controls Moreover, both studies were prospective, and slight 371 
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differences between the prospective and retrospective studies were highlighted by the sub 372 
analyses carried out (Table 2). For adiponectin, the SOR was 0.64 for prospective studies 373 
compared to 0.45 for retrospective with statistical difference for retrospective studies 374 
(p=0.0001) and for leptin, the SOR for prospective studies was 3.32 (p<0.00001) compared to 375 
1.67 (p=0.02) for retrospective studies. 376 
There have been limited studies assessing TNF-α and IL-6 and its risk with endometrial cancer. 377 
TNF-α and IL-6 play an important role in promoting carcinogenesis through the activation of 378 
various transcription factors and multiple oncogenic pathways. However, no significant 379 
associations between these two markers and risk of cancers were observed in the current meta-380 
analysis. Despite the limited number of studies, the number of endometrial cancer cases and 381 
controls were relatively high; 940 vs 1781 and 975 vs 1837 cases vs controls, respectively. 382 
When assessing the individual studies, Wang et al., 2011 [35] and Friedenreich et al., 2013 [50] 383 
did not find an association between TNFα and IL-6 which is in contrast to the studies conducted 384 
by Dossus et al., 2010, 2011 [33, 34]. The risk of endometrial cancer appears not to be initiated 385 
by TNFα and IL-6, but may develop through other inflammatory pathways, such as genetic 386 
aberrations in PTEN or NFκB genes and the increased production of other mediators of 387 
inflammation [57]. Similar results related to the association of increased risk of endometrial 388 
cancer with TNF-α and IL-6 were also found in a recent systematic review and meta-analysis 389 
on circulating adipokines and their risk to obesity related cancers including breast, colorectal, 390 
kidney pancreatic, prostate, endometrial, and multiple myeloma cancers [58]. 391 
The only study considering the association of circulating levels of IGF-I with endometrial 392 
cancer, showed no association, in agreement with a study by Petridou et al., [59] which showed 393 
that endometrial cancer was positively associated with IGF-II and inversely with IGF-I. This 394 
study adds to the gradually developing consensus that components of the IGF system play a 395 
central role in human carcinogenesis, and that IGF-II, rather than IGF-I, may be closely linked 396 
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to the aetiology of endometrial cancer, one of the types of cancer most strongly associated with 397 
obesity. 398 
Different study populations have differing characteristics, including BMI levels and presence 399 
of hypertension and diagnosis of diabetes. Further sub-analyses were performed to identify any 400 
other factors that could affect the risk of endometrial cancer. Tables 2 summarises the OR of 401 
the association between circulating adiponectin, leptin and endometrial cancer stratified by 402 
study characteristics. BMI appeared to affect the association between circulating leptin levels 403 
and endometrial cancer risk, but not with circulating adiponectin levels and endometrial cancer 404 
risk. Hypertension and diabetes appear to affect the association between circulating leptin levels 405 
but not between adiponectin levels and increased endometrial cancer risk. Adiponectin and 406 
leptin may act synergistically and increase the risk of endometrial cancer. This is not the case 407 
for TNF-α and IL-6.  408 
The strength of our research is that this study presents a relatively comprehensive review of the 409 
existing evidence on the association of various adipocytokines and endometrial cancer. In 410 
particular, stratified analysis using a variety of selected variables has strengthened our results 411 
against the influence of confounding. There were also limitations to the meta-analysis; the 412 
number of cases in each study was relatively small, however the overall number of endometrial 413 
cancer cases in the meta-analysis was high, 2921. Retrospective studies were included and 414 
therefore, there is always a risk of potential bias in the form of recall bias.  415 
This meta-analysis is the first to assess multiple adipocytokines in relation to endometrial 416 
cancer risk. Larger prospective studies assessing a variety of adipocytokines in the same cohort 417 
of patients are required to investigate further the association between adipocytokines and 418 
endometrial cancer, especially studies considering circulating levels of TNF-α, IL-6 and IGF I 419 
and II. This would allow elucidating in more details, the exact mechanisms underlying the link 420 
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Table 1 616 
Characteristics of included articles (n=20) 617 













Risk Estimates  
(95% CI)  
Exposure 
categories 











OR 0.822  
(0.759-0.889)  
Not specified in text 












OR 1.987  
(0.290-13.617) 
Q1 vs Q2 














OR 10.64  
(3.61-31.40) 
T1 vs T3 














OR 1.00  
(0.84-1.18) 
OR 1.15  
(0.89-1.48) 
Not specified in text 
Age, BMI, nulliparity, physical activity, 













OR 0.52  
(0.32-0.83) 
OR 2.05  
(1.28-3.29) 
T3 vs T1 
Age, BMI, glucose, cholesterol, 
triglycerides, HDL cholesterol, insulin, 









514/961 59 (53, 65)c 
59 (52, 66)c 
31.0 (26.4,36.8)c 





OR 0.55  
(0.37-0.80) 
OR 1.14  
(0.73-1.77) 
Q4 vs Q1 
Age, weight, waist to hip ratio, nulliparity, 
HRT, hypertension, glucose, insulin, 















OR 0.6  
(0.3-1.2)  
OR 2.6  
(1.4-4.9) 
T3 vs T1 












OR 10.5  
(4.18-26.35) 
T1 vs T3 
Age, BMI, diabetes, hypertension, 













T3 vs T1 







84/84 n/a n/a Adiponectin  
(RIA) 
OR 0.78  
(0.56-1.10) 
1SD increment 
Age, BMI, height, education, age at 
menarche, pregnancy, IGF-I, IGF-II, 












OR 1.13  
(0.70-1.81) 
1SD increment 
Age, education, height, age at menarche, 
menopausal status, history of pregnancy 
by outcome, alcohol and coffee 














OR 0.07  
(0.01-0.62) 
OR 10.68  
(2.09-54.67) 
T3 vs T1 













OR 0.98  
(0.57-1.68) 
T3vs T1 
















OR 0.87  
(0.39-1.94) 
OR 3.29  
(1.41-7.69) 
T3 vs T1 

















OR 0.48  
(0.29-0.80) 
OR 2.77  
(1.60-4.79) 
T3 vs T1 
Age, HRT, current smoking status, family 
history of breast and endometrial cancer, 












TNFα   
(ELISA) 
OR 1.73  
(1.09-2.73) 
Q4 vs Q1 
Age, BMI, nulliparity, age at menopause, 















OR 0.70  
(0.29-1.68) 
OR 1.65  
(0.77 - 3.54) 
Q4 vs Q1 







305/574 56.9 (7.3)a 
57.1 (7.4)a 




OR 1.66  
(1.08-2.54) 
Q4 vs Q1 
















OR 0.63  
(0.36-1.10) 
Q4 vs Q1 
Age, BMI, C-peptide, IGFBP-1, IGFBP-2, 













OR 0.90  
(0.44-1.82) 
Q5 vs Q1 
Age, menopausal status, day of menstrual 
cycle for pre-menopausal women 
BMI, body mass index; WHR, waist-to-hip-ratio; ELISA ,enzyme linked immunosorbent assay; HOMA-IR, homeostasis model assessment of insulin 618 
resistance; QUICKI, quantitative insulin sensitivity check index; IGF, insulin like growth factor; IGFBP, insulin like growth factor binding protein; SHBG, 619 
sex hormone binding globulin; HRT, hormone replacement therapy; OR , odds ratio; RIA, radio-immuno assay. 620 
a: mean ± SD; b: mean (range); c: median (25th, 75th percentile); d: median (range); e: median (interquartile range); f: mean (5th-95th percentiles); g: mean (95% 621 
confidence interval); n/a: not available 622 
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Table 2 624 
Summary of OR of the relationship between adiponectin or leptin and possible risk factors for endometrial cancer  625 
Adiponectin Leptin 
No of study SOR 95% CI I2 1p value 2p value 
No of 
study SOR 95% CI I
2 1p value 2p value 
Study design 
Prospective 5 0.64 0.41-0.99 56% p=0.06 p=0.27 3 3.32 1.98-5.56 15% p=0.31 p=0.04 
Retrospective 9 0.45 0.29-0.68 83% P<0.00001 4 1.67 1.09-2.57 56% p=0.08 
Fasting blood samples 
Yes 8 0.51 0.34-0.76 52% p=0.04 p=1 6 2.10 1.31-3.38 65% p=0.01 n/a 
No 6 0.51 0.32-0.81 85% p<0.00001 1 2.77 1.60-4.80 n/a n/a 
Assay method 
ELISA 11 0.53 0.38-0.75 79% p<0.00001 p=0.52 4 2.27 1.16-4.42 75% p=0.007 p=0.85 
RIA/IMRA 3 0.45 0.31-0.65 0% p=0.45 3 2.45 1.67-3.59 0% p=0.45 
BMI  
Yes 11 0.46 0.31-0.69 81% P<0.00001 p=0.31 4 2.35 1.43-3.88 39% p=0.18 p=0.76 
No 3 0.59 0.45-0.76 0% p=0.46 3 2.05 0.99-4.25 80% p=0.007 
Hypertension 
Yes 6 0.57 0.36-0.91 81% P<0.0001 p=0.54 3 1.99 0.98-4.04 76% p=0.02 p=0.66 
No 8 0.47 0.31-0.70 64% p=0.007 4 2.42 1.47-3.97 42% p=0.16 
Diabetes 
Yes 7 0.6 0.38-0.94 79% P<0.001 p=0.31 3 2.80 1.93-4.05 0% p=0.91 p=0.23 




Yes 9 0.56 0.40-0.80 70% p=0.0007 p=0.47 5 2.75 1.87-4.05 16% p=0.31 P=0.09 
No 5 0.44 0.25-0.81 81% p=0.0004 2 1.49 0.83-2.70 73% P=0.05 
1 p value for heterogeneity within each subgroup; 2p values for heterogeneity between subgroups with meta-regression analysis 626 
33 
 
Figure legends 627 
Figure 1: Flow diagram of screened, excluded and analysed publications 628 
Figure 2: Forest plots representing the association between circulating levels of adiponectin 629 
and the risk of endometrial cancer risk. The red squares represent the OR of the individual 630 
studies and the horizontal lines through the boxes represent the 95% coefficient interval. The 631 
overall treatment effect is represented by the black diamond. 632 
Figure 3: Forest plots representing the association between circulating levels of leptin and the 633 
risk of endometrial cancer risk. Red squares represent the OR of the individual studies and the 634 
horizontal lines through the boxes represent the 95% coefficient interval. The overall treatment 635 
effect is represented by the black diamond.  636 
Figure 4: Forest plots representing the association between circulating levels of TNFα (A) or 637 
IL-6 (B) and the risk of endometrial cancer risk. The red squares represent the OR of the 638 
individual studies and the horizontal lines through the boxes represent the 95% coefficient 639 
interval. The overall treatment effect is represented by the black diamond. 640 




